Pharmacotherapeutical Study and Intricacy of Allergic Rhinitis
Department of pharmacy, Bhupal Nobles’ University, Udaipur, Rajasthan, India
*Corresponding Author: Kishan Labana, Department of pharmacy, Bhupal Nobles’ University, Udaipur, Rajasthan, India.
April 11, 2022; Published: April 22, 2022
Allergic rhinitis is an immunologically mediated disease initiated by an antigen and antibody reaction in hyperactive individuals. Allergic rhinitis (AR) is estimated to affect between 10 and 40% of the population [1,2]. Characterized by sneezing, rhinorrhea, nasal obstruction. In this study we observed how this persistent symptoms leads to development of major complications like nasal polyps and asthma. Study also suggest the progression of complications in different age groups of allergic rhinitis patients. Various treatment is available for AR and also there has been little improvement in patients quality of life. The selection for treatment for AR patients aims to control the symptoms.
Keywords: Hyperactive; Persistent; Sneezing; Nasal Polyps; Asthma; Quality of Lifeconsumption
- Bjorksten B., et al. “Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the international study of asthma and allergies in childhood”. Pediatric Allergy and Immunology 19 (2008): 110-124.
- Bernstein J A. “Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability”. Current Medical Research and Opinion 23 (2007): 2441-2452.
- Dykewicz MS and Hamilos DL. “Rhinitis and sinusitis”. The Journal of Allergy and Clinical Immunology 125 (2010): S103-115.
- Meltzer EO. “Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control”. Immunology and Allergy Clinics of North America 36 (2016): 235-248.
- Small P., et al. “Rhinitis: a practical and comprehensive approach to assessment and therapy”. Journal of Otolaryngology 36 (2007): S5-27.
- Frew AJ. “Allergen immunotherapy”. The Journal of Allergy and Clinical Immunology 125 (2010): S306-313.
- Pullerits T., et al. “Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis”. American Journal of Respiratory and Critical Care Medicine 6 (1999): 1814-1818.
- Ratner PH., et al. “Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast”. Annals of Allergy, Asthma and Immunology 5 (2005): 536-542.
- Wilson AM., et al. “A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma”. Clinical and Experimental Allergy 4 (2001): 616-624.
- Bousquet J., et al. “Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2)LEN and AllerGen)”. Allergy 86 (2008): 8-160.
- Kim H and Kaplan A. “Treatment and management of allergic rhinitis [feature]”. Clinical Focus (2008): 1-4.
- Horak F., et al. “Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy”. Current Medical Research and Opinion 22 (2006): 151-157.
- Patel D., et al. “Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate”. Allergy and Asthma Proceedings 28 (2007a): 592-599.
- Greiff L., et al. “Topical azelastine has a 12- hour duration of action as assessed by histamine challenge-induced exudation of alpha 2- macroglobulin into human nasal airways”. Clinical and Experimental Allergy 27 (1997): 438-444.
- Patel P., et al. “An assessment of the onset and duration of action of olopatadine nasal spray”. Otolaryngology–Head and Neck Surgery 137 (2007c): 918-924.
- Derendorf H and Meltzer EO. “Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications”. Allergy 63 (2008): 1292-1300.